The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models

Fabry disease is an X-linked multisystemic disorder caused by the impairment of lysosomal α-Galactosidase A, which leads to the progressive accumulation of glycosphingolipids and to defective lysosomal metabolism. Currently, Fabry disease is treated by enzyme replacement therapy or the orally admini...

Full description

Bibliographic Details
Main Authors: Pedro Besada, María Gallardo-Gómez, Tania Pérez-Márquez, Lucía Patiño-Álvarez, Sergio Pantano, Carlos Silva-López, Carmen Terán, Ana Arévalo-Gómez, Aurora Ruz-Zafra, Julián Fernández-Martín, Saida Ortolano
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Biomolecules
Subjects:
Fabry disease
pharmacological chaperones
<i>GLA</i> variants
Migalastat
lysosomal storage diseases
Online Access:https://www.mdpi.com/2218-273X/11/12/1856

Internet

https://www.mdpi.com/2218-273X/11/12/1856

Similar Items